ABSTRACT:
Sulfasalazine is the first line treatment for Inflammatory Bowel syndrome. Conventional formulation have poor targeting properties for colon site.Therefore designof colon specific nanoparticles (NP) is an ideal for better therapeutic outcome. The study aims to formulate and evaluate polymeric Nanoparticles loaded with Sulfasalazine to target the colon. The nanoparticles were prepared by Nano-precipitation method using pH dependent polymer and the prepared nanoparticles were evaluated for FTIR, morphology, pH, Viscosity, Entrapment efficiency, particle size and zeta potential etc. The nanoparticles were used to formulate core tablet and core tablets were coated with Eudragit S100. The tablets were evaluated for hardness, friability, thickness, weight variation and In vitro release study. Totally six formulations were developed for preliminary trial with varying concentration of polymers. From the preliminary trial, code F2batch was found to be best formulation. The F2batch was fitted to central composite design with two independent factors i.e. Concentration of Eudragit S100 (X1) and polyvinyl alcohol (X2) with four dependent variables i.e. Entrapment efficiency -Y1; Hardness- Y2; Friability-Y3 and In-vitro drug release- Y4. The formulation (code R6) was found to be the optimizedformulation. The optimized colon targeted tablets provide satisfactory release and might be suitable for colon targeting of sulfasalazine with better therapeutic effect.
Cite this article:
Sivakumar R, Shafin P. Design of Colon Specific Delivery of Sulfasalazine Loaded Nanoparticles for Inflammatory Bowel Syndrome: Application of Experimental Design. Research Journal of Pharmacy and Technology. 2024; 17(3):1272-6. doi: 10.52711/0974-360X.2024.00199
Cite(Electronic):
Sivakumar R, Shafin P. Design of Colon Specific Delivery of Sulfasalazine Loaded Nanoparticles for Inflammatory Bowel Syndrome: Application of Experimental Design. Research Journal of Pharmacy and Technology. 2024; 17(3):1272-6. doi: 10.52711/0974-360X.2024.00199 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-3-50
REFERENCES:
1. Choudhury A. Laskar RE. Deka D. Sonowal K. Saha S. Dey BK. A review on nanoparticle: Types, preparation and its characterization. Research Journal of Pharmacy and Technology. 2021; 14(3):1815-22.DOI: 10.5958/0974-360X.2021.00322.X
2. Renu Tiruwa. A review on nanoparticles – preparation and evaluation parameters.Indian Journal of Pharmaceutical and Biological Research 2015; 4(2):27-31.https://doi.org/10.30750/ijpbr.4.2.4
3. Ibrahim AH, Smått JH, Govardhanam NP, Ibrahim HM, Ismael HR et al.Formulation and optimization of drug-loaded mesoporous silica nanoparticle-based tablets to improve the dissolution rate of the poorly water-soluble drug silymarin. European Journal of Pharmaceutical Sciences. 2020; 142:105103.https://doi.org/10.1016/j.ejps.2019.105103
4. Markam R, Bajpai AK. Functionalization of ginger derived nanoparticles with chitosan to design drug delivery system for controlled release of 5-amino salicylic acid (5-ASA) in treatment of inflammatory bowel diseases: An in vitro study. Reactive and functional polymers. 2020; 149:104520.https://doi.org/10.1016/j.reactfunctpolym.2020.104520.
5. Jain P, Parkhe G. Alternative colon targeted drug delivery approaches for the treatment of inflammatory bowel disease. Research Journal of Pharmacy and Technology. 2020;13(11):5562-5568DOI: 10.5958/0974-360X.2020.00971.3
6. Iyengar KR, Komala M, Satheeshkumar S. Colon specific drug delivery systems-different systems and approaches: A review. Research Journal of Pharmacy and Technology. 2020; 13(12):6248-6258.DOI: 10.5958/0974-360X.2020.01089.6
7. Ghasemi S, Farsangi ZJ, Beitollahi A, Mirkazemi M, Rezayat SM, Sarkar S. Synthesis of hollow mesoporous silica (HMS) nanoparticles as a candidate for sulfasalazine drug loading. Ceramics International. 2017; 43(14):11225-11232.https://doi.org/10.1016/j.ceramint.2017.05.172
8. Yadav AK, Sadora M, Singh SK, Gulati M, Maharshi P et al. Novel biorelevant dissolution medium as a prognostic tool for polysaccharide-based colon-targeted drug delivery system. Journal of Advanced Pharmaceutical Technology & Research. 2017; 8(4):150-155.doi: 10.4103/japtr.JAPTR_70_17
9. Barros PD, Dias IF, Zanin GD, Bunhak ÉJ. Development and evaluation of dapsone tablets coated for specific colon release. Drug Development and Industrial Pharmacy .2020; 46(2):246-52.DOI: 10.1080/03639045.2020.1716375
10. Guo JJ, Yue PF, Lv JL, Han J, Fu SS et al . Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension. International journal of pharmaceutics. 2013 Jan 30; 441(1-2):227-33.https://doi.org/10.1016/j.ijpharm.2012.11.039
11. Fukui E, Miyamura N, Uemura K, Kobayashi M. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting.International journal of pharmaceutics. 2000;204(1-2):7-15.https://doi.org/10.1016/S0378-5173(00)00454-3
12. Alvarez-Fuentes J, Fernández-Arévalo M, González-Rodríguez ML, Cirri M, Mura P. Development of enteric-coated timed-release matrix tablets for colon targeting. Journal of drug targeting. 2004;12(9-10):607-12.DOI: 10.1080/10611860400013501
13. Nunthanid J. Laungtana-Anan M. Sriamornsak P. Limmatvapirat S. Puttipipatkhachorn S. Lim LY. Khor E. Characterization of chitosan acetate as a binder for sustained release tablets. Journal of Controlled Release. 2004;99(1):15-26.https://doi.org/10.1016/j.jconrel.2004.06.008
14. Dahlberg, A. Fureby, M. Schuleit, S. V. Dvinskikh. Polymer mobilization and drug release during tablet swelling. J. Control. Release. 2007, 1(2), 199–205. DOI: 10.1016/j.jconrel.2007.07.007